|Other Names||Anterior gradient protein 2 homolog, AG-2, hAG-2, HPC8, Secreted cement gland protein XAG-2 homolog, AGR2, AG2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6279a was selected from the N-term region of human AGR2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells (By similarity). Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth.|
|Cellular Location||Secreted. Endoplasmic reticulum|
|Tissue Location||Expressed strongly in trachea, lung, stomach, colon, prostate and small intestine. Expressed weakly in pituitary gland, salivary gland, mammary gland, bladder, appendix, ovary, fetal lung, uterus, pancreas, kidney, fetal kidney, testis, placenta, thyroid gland and in estrogen receptor (ER)-positive breast cancer cell lines.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Anterior gradient 2 (AGR2) is known as a cancer cell marker specifically up-regulated in response to depletion of serum and oxygen. AGR2 has been identified as a tumor marker in primary and secondary cancer lesions, and as a marker for detection of circulating tumor cells (CTCs). Elevated levels of AGR2 are known to increase the metastatic potential of cancer cells, but conditions leading to increased expression of AGR2 are not well understood.
Zweitzig,D.R., Mol. Cell. Biochem. 306 (1-2), 255-260 (2007)Zhang,Y., Prostate Cancer Prostatic Dis. 10 (3), 293-300 (2007)Fletcher,G.C., Br. J. Cancer 88 (4), 579-585 (2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.